Which has stronger valuation and earnings, LQDA or HCM?

HUTCHMED has higher revenue and earnings than Liquidia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 51.46 -$68.92M $0.14 654.42 HUTCHMED $548.51M 4.00 $456.91M N/A N/A

Is LQDA or HCM more profitable?

Liquidia has a net margin of 7.74% compared to HUTCHMED's net margin of 0.00%. Liquidia's return on equity of 46.82% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 7.74% 46.82% 7.06% HUTCHMED N/A N/A N/A

Does the media refer more to LQDA or HCM?

In the previous week, Liquidia had 8 more articles in the media than HUTCHMED. MarketBeat recorded 11 mentions for Liquidia and 3 mentions for HUTCHMED. Liquidia's average media sentiment score of 0.99 beat HUTCHMED's score of 0.35 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, HCM or LNTH?

HUTCHMED has higher earnings, but lower revenue than Lantheus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.00 $456.91M N/A N/A Lantheus $1.54B 4.27 $233.56M $4.14 24.38

Is HCM or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 28.10% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Lantheus 17.69% 28.10% 14.35%

Does the media prefer HCM or LNTH?

In the previous week, Lantheus had 14 more articles in the media than HUTCHMED. MarketBeat recorded 17 mentions for Lantheus and 3 mentions for HUTCHMED. Lantheus' average media sentiment score of 0.52 beat HUTCHMED's score of 0.35 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 6 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, BLTE or HCM?

HUTCHMED has higher revenue and earnings than Belite Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A HUTCHMED $548.51M 4.00 $456.91M N/A N/A

Is BLTE or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% HUTCHMED N/A N/A N/A

Does the media favor BLTE or HCM?

In the previous week, Belite Bio had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for HUTCHMED. Belite Bio's average media sentiment score of 0.77 beat HUTCHMED's score of 0.35 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, HCM or AMRX?

HUTCHMED has higher earnings, but lower revenue than Amneal Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.00 $456.91M N/A N/A Amneal Pharmaceuticals $3.02B 1.91 $72.06M $0.49 36.79

Does the media prefer HCM or AMRX?

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 3 mentions for HUTCHMED. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat HUTCHMED's score of 0.35 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, HCM or EWTX?

HUTCHMED has higher revenue and earnings than Edgewise Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.00 $456.91M N/A N/A Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A

Is HCM or EWTX more profitable?

HUTCHMED's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets HUTCHMED N/A N/A N/A Edgewise Therapeutics N/A -39.01% -36.96%

Does the media prefer HCM or EWTX?

In the previous week, Edgewise Therapeutics had 15 more articles in the media than HUTCHMED. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.35 beat Edgewise Therapeutics' score of -0.24 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

HUTCHMED (HCM) Competitors

$12.59 +0.08 (+0.64%)

As of 03:41 PM Eastern

Compare

HCM vs. LQDA, LNTH, BLTE, AMRX, and EWTX

Should you buy HUTCHMED stock or one of its competitors? MarketBeat compares HUTCHMED with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HUTCHMED include Liquidia (LQDA), Lantheus (LNTH), Belite Bio (BLTE), Amneal Pharmaceuticals (AMRX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceuticals" industry.

How does HUTCHMED compare to Liquidia?

Liquidia (NASDAQ:LQDA) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Liquidia had 8 more articles in the media than HUTCHMED. MarketBeat recorded 11 mentions for Liquidia and 3 mentions for HUTCHMED. Liquidia's average media sentiment score of 0.99 beat HUTCHMED's score of 0.35 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Liquidia has a net margin of 7.74% compared to HUTCHMED's net margin of 0.00%. Liquidia's return on equity of 46.82% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
HUTCHMED	N/A	N/A	N/A

Liquidia currently has a consensus target price of $86.18, indicating a potential downside of 5.93%. HUTCHMED has a consensus target price of $14.87, indicating a potential upside of 18.08%. Given HUTCHMED's higher possible upside, analysts plainly believe HUTCHMED is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

HUTCHMED has higher revenue and earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	51.46	-$68.92M	$0.14	654.42
HUTCHMED	$548.51M	4.00	$456.91M	N/A	N/A

Summary

Liquidia beats HUTCHMED on 12 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Lantheus?

HUTCHMED (NASDAQ:HCM) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

HUTCHMED has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

In the previous week, Lantheus had 14 more articles in the media than HUTCHMED. MarketBeat recorded 17 mentions for Lantheus and 3 mentions for HUTCHMED. Lantheus' average media sentiment score of 0.52 beat HUTCHMED's score of 0.35 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	6 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

HUTCHMED has higher earnings, but lower revenue than Lantheus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.00	$456.91M	N/A	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.38

HUTCHMED presently has a consensus price target of $14.87, suggesting a potential upside of 18.08%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.13%. Given HUTCHMED's higher possible upside, equities research analysts clearly believe HUTCHMED is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Lantheus has a net margin of 17.69% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 28.10% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Lantheus	17.69%	28.10%	14.35%

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Lantheus beats HUTCHMED on 10 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

HUTCHMED has higher revenue and earnings than Belite Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
HUTCHMED	$548.51M	4.00	$456.91M	N/A	N/A

Belite Bio currently has a consensus target price of $203.00, suggesting a potential upside of 21.88%. HUTCHMED has a consensus target price of $14.87, suggesting a potential upside of 18.08%. Given Belite Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Belite Bio is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

In the previous week, Belite Bio had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for HUTCHMED. Belite Bio's average media sentiment score of 0.77 beat HUTCHMED's score of 0.35 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has a beta of -1.22, meaning that its stock price is 222% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

HUTCHMED's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
HUTCHMED	N/A	N/A	N/A

Summary

Belite Bio and HUTCHMED tied by winning 6 of the 12 factors compared between the two stocks.

How does HUTCHMED compare to Amneal Pharmaceuticals?

HUTCHMED (NASDAQ:HCM) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

HUTCHMED has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 3 mentions for HUTCHMED. Amneal Pharmaceuticals' average media sentiment score of 1.36 beat HUTCHMED's score of 0.35 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

HUTCHMED has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.00	$456.91M	N/A	N/A
Amneal Pharmaceuticals	$3.02B	1.91	$72.06M	$0.49	36.79

Amneal Pharmaceuticals has a net margin of 5.05% compared to HUTCHMED's net margin of 0.00%. HUTCHMED's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

HUTCHMED presently has a consensus target price of $14.87, suggesting a potential upside of 18.08%. Amneal Pharmaceuticals has a consensus target price of $17.67, suggesting a potential downside of 2.00%. Given HUTCHMED's higher possible upside, research analysts plainly believe HUTCHMED is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

Summary

Amneal Pharmaceuticals beats HUTCHMED on 10 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Edgewise Therapeutics?

HUTCHMED (NASDAQ:HCM) and Edgewise Therapeutics (NASDAQ:EWTX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

HUTCHMED's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Edgewise Therapeutics	N/A	-39.01%	-36.96%

HUTCHMED has higher revenue and earnings than Edgewise Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.00	$456.91M	N/A	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

8.8% of HUTCHMED shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

HUTCHMED has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

In the previous week, Edgewise Therapeutics had 15 more articles in the media than HUTCHMED. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.35 beat Edgewise Therapeutics' score of -0.24 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

HUTCHMED currently has a consensus price target of $14.87, suggesting a potential upside of 18.08%. Edgewise Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 9.13%. Given HUTCHMED's higher possible upside, research analysts clearly believe HUTCHMED is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

HUTCHMED beats Edgewise Therapeutics on 7 of the 12 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCM vs. The Competition

Export

Metric	HUTCHMED	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.20B	$11.92B	$7.04B	$12.94B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	N/A	788.54	269.98	24.78
Price / Sales	4.00	968.40	651.07	108.19
Price / Cash	4.64	15.12	28.89	37.44
Price / Book	1.76	10.32	11.26	6.43
Net Income	$456.91M	$2.77B	$3.45B	$347.27M
7 Day Performance	9.00%	2.00%	3.50%	2.54%
1 Month Performance	13.73%	-1.57%	-0.64%	-1.00%
1 Year Performance	-16.07%	191.20%	77.23%	23.33%

HUTCHMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCM HUTCHMED	1.9826 of 5 stars	$12.59 +0.6%	$14.87 +18.1%	-16.6%	$2.20B	$548.51M	N/A	1,796	Analyst Upgrade Gap Up
LQDA Liquidia	3.3733 of 5 stars	$87.09 +3.9%	$86.18 -1.0%	+341.2%	$7.76B	$158.32M	623.09	50	Upcoming Earnings Gap Up
LNTH Lantheus	2.9163 of 5 stars	$101.27 +0.1%	$108.11 +6.8%	+76.5%	$6.60B	$1.54B	24.41	1,193	Positive News Earnings Report Gap Down
BLTE Belite Bio	3.2157 of 5 stars	$156.55 +1.1%	$203.00 +29.7%	+133.3%	$6.27B	N/A	N/A	10
AMRX Amneal Pharmaceuticals	3.3964 of 5 stars	$18.47 -2.0%	$17.67 -4.3%	+112.4%	$5.92B	$3.02B	37.86	8,500	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCM) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HUTCHMED (HCM) Competitors